



**CARTOX Cell Therapy Group Active IEC Therapy Protocol and Patient Reviews - 12/15/2022
 12/15/2022 4:00:00 PM - 12/15/2022 5:30:00 PM**

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact PEPInfo@mdanderson.org.

Learning Objectives:

- 1 Utilize the current IEC treatment guidelines and, most agreed upon, good practices.
- 2 Assess patient cases and their outcomes.
- 3 Identify the development trend of IEC therapy and new modalities emerging for clinical studies.
- 4 Identify common issues and implement corrective plans.

Accreditation:

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:

No commercial support has been received for this activity.

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Sattva S Neelapu, MD	Activity Co-Director	Grant or research support-Gilead Sciences, Inc. Grant or research support-Bristol-Myers Squibb Company Consulting Fee-Gilead Sciences, Inc. Consulting Fee-Astellas Scientific and Medical Affairs, Inc. Consulting Fee-Bristol-Myers Squibb Company Consulting Fee-Incyte Corporation (Relationship has ended) Consulting Fee-Janssen Biotech, Inc. Royalties or Patent Beneficiary-Millennium Pharmaceuticals, Inc., The Takeda Oncology Company (Relationship has ended) Consulting Fee-Novartis

		Pharmaceuticals Corporation (Relationship has ended) Consulting Fee-Pfizer Inc. (Relationship has ended) - 10/10/2022
Elizabeth J Shpall, MD	Activity Director, Faculty	Nothing to disclose - 11/09/2022
Peter H Norman, MD, FRCPC FASA	CE Reviewer	Nothing to disclose - 11/04/2022
Sherry Adkins, MSN, ANP-C	Other Planning Committee Member	Nothing to disclose - 12/14/2022
Alison M Gulbis, PharmD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-EUSA Pharma (Relationship has ended) - 12/07/2022
Partow Kebriaei, MD	Other Planning Committee Member	Honoraria-Pfizer Inc. Honoraria-Jazz Pharmaceuticals - 12/08/2022
Melinda R Pena, AAS, CAP, OM	Other Planning Committee Member	Nothing to disclose - 10/04/2022
Jason Westin, MD	Other Planning Committee Member	Grant or research support-AstraZeneca US Grant or research support-Merck Sharp & Dohme Corp. (any division) (Relationship has ended) Grant or research support-MonteRosa (Relationship has ended) Paid consultant-ADC Therapeutics Paid consultant-Morphosys Paid consultant-Novartis Pharmaceuticals Corporation Paid consultant-Gilead Sciences, Inc. Paid consultant-Genentech, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-Iksuda Grant or research support-Johnson & Johnson (any division) Grant or research support-Gilead Sciences, Inc. Grant or research support-Bristol-Myers Squibb Company Grant or research support-Morphosys Grant or research support-Unum (Relationship has ended) Grant or research support-Genentech, Inc. - 10/04/2022
William G Wierda, MD, PhD	Other Planning Committee Member	Nothing to disclose - 12/15/2022
Biju Yang, PhD	Other Planning Committee Member	Nothing to disclose - 10/04/2022